Vargas-Viveros P, Hurtado-Monroy R, Candelaria-Hernández MG

Language: Spanish
References: 14
Page: 363-369
PDF size: 209.82 Kb.

ABSTRACT

Background: Myeloproliferative neoplasms can shorten the life of patients and affect severely their quality of life as a result of the severe constitutional symptoms mediated by cytokines resulting from massive splenomegaly characteristic of these diseases. The objective measurement of symptoms of myelofibrosis is essential for the presence of general constitutional symptoms and for assessing the outcome of treatment with JAK-2 inhibitors.
Objective: To assess the impact on quality of life in patients with myeloproliferative neoplasms treated with the inhibitor of JAK-1 and JAK-2 ruxolitinib.
Material and method: There was applied the questionnaire Myelofibrosis Symptom Assessment Form to 16 patients included in the Compassionate Use of Ruxolitinib Program: eight men and eight women were included with a median age of 63 years; four patients had primary myelofibrosis, three had postpolycythemia vera myelofibrosis and nine essential postthrombocythemia myelofibrosis. The patients started with a dose of 20 mg ruxolitinib orally every 12 hours.
Results: The questionnaire was administered to all patients at each visit. By comparing the differences of each parameter measured between the start and at 3, 6 and 12 months were statistically significant for all variables (p ‹ 0.001, 95%). The most significant changes were observed when comparing data at baseline and follow-up to the maximum time; however, were obvious from the first quarter of observation on fatigue and symptoms of splenomegaly in most general symptoms, which disappeared completely after three months of treatment. The variables with lower proportional change recorded were general activity, mood, walking tolerance and everyday work.
Conclusions: The treatment of myeloproliferative neoplasms with ruxolitinib represents a major advance in the management of myeloproliferative diseases and achieved excellent improvement in overall constitutional symptom control, splenomegaly and the general perception of the quality of life of these patients. The objective measurement of symptoms of myelofibrosis is essential for assessing the outcome of treatment with inhibitors JAK-2.

REFERENCES

1. Tefferi A, Lasho TL, Schwager SM, Strand JS, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631-635.

2. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-166.

3. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999;61:10-15.

4. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006;106:623-630.

5. Mesa RA, Verstovsek S, Cervantes F, Barosi G, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007;31:737-740.

6. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010;91:165-173.

7. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008;19:385-393.

8. Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol 2012;5:631-641.

9. Tefferi A, Barosi G, Ruben A, Cervantes F, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-1503.

10. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 2012;8:95-103.

11. Mesa RA, Schwager S, Radia D, Cheville A, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-1203.

12. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, et al. The burden of fatigue and quality of life in Myeloproliferative Disorders (MPDs). An international internet-based survey of 1179 MPD Patients. Cancer 2007;109:68-76.

13. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for Myelofibrosis. N Engl J Med 2012;366:799-807.

14. Deisseroth A, Kaminskas E, Grillo J, Chen W, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012;18:3212–3217.